HSCS
HeartSciences Inc.
HSCS Q1 2027 earnings
Published Sep 15, 2026
AI summary
- HeartSciences reported no meaningful revenue for the first fiscal quarter of 2027.
- The company recorded a net loss of 3.2 million dollars for the quarter.
- The proposed business combination with Fortitude is expected to close in the fourth calendar quarter of 2026.
- Commercial efforts are now focused on the MyoVista Insights platform, with first US agreements signed.
Results vs analyst consensus
Revenue
Not reported in this release.
EPS
Not reported in this release.
Consensus: Yahoo Finance · Q1 2027
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company recorded a 0.3 million dollar reserve against the carrying value of MyoVista device inventory.
- Operating losses increased due to transaction costs, share-based compensation, and inventory reserves.
- The company reported a shareholders' deficit of 2.0 million dollars as of July 31, 2026.
Read original report
Source: HeartSciences Inc. press release · SEC Form 8-K exhibit 99.1